索非布韋/達卡他韋
 Sovodak 60/400 | |
| 组成 | |
|---|---|
| 達卡他韋 | NS5A 抑制劑 |
| 索非布韋 | NS5B (RNA聚合酶) 抑制劑 |
| 臨床資料 | |
| 商品名 | Darvoni,[1] Sovodak |
| 给药途径 | Oral |
| 识别信息 | |
| CAS号 | 2306918-02-3 |
索非布韋/達卡他韋（daclatasvir/sofosbuvir，SOF/DCV）用于治疗丙型肝炎的複方藥[2]。它是第一线治疗，对所有亚型均有效[3]。療效 90% 以上[2]。適用年齡至少需 3 岁以上[4]。通常每天口服一次，连续服用 12 周，可以服用一粒複方药或兩種各別成份的藥物[5] [2]。
常见副作用包括头痛、疲倦、恶心和腹痛[5]。严重副作用并不常见[5]。虽未发现孕期使用有害，但研究尚不充分[6] [7]。此药物內含達卡他韋（一种病毒非結構蛋白5A抑制剂） [8]和索非布韋（一种病毒非結構蛋白5BRNA聚合酶的核苷酸抑制剂）[9]。
至 2022 年為止，它是发展中国家最常用的丙型肝炎疗法[3]。但這個组合药物未在美国取得醫療使用許可，在美国于 2019 年停止销售達卡他韋[10]。名列世界卫生组织基本药物标准清单[11]。
参考文獻
[编辑]- ^ Home. Darvoni - Beacon Medicare Limited.
- ^ 2.0 2.1 2.2 Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepatic Medicine: Evidence and Research. 2016, 8: 21–26. PMC 4786064
. PMID 27019602. doi:10.2147/HMER.S62014.
- ^ 3.0 3.1 Hepatitis C. www.who.int. [2 December 2022]. （原始内容存档于26 May 2020） （英语）.
- ^ WHO publishes updated guidance on hepatitis C infection – with new recommendations on treatment of adolescents and children, simplified service delivery and diagnostics. www.who.int. [2 December 2022]. （原始内容存档于6 October 2022） （英语）.
- ^ 5.0 5.1 5.2 Application for Inclusion of Sofosbuvir/Daclatasvir on the WHO Model List of Essential Medicines for Children (EMLc) (PDF). [2 December 2022]. （原始内容存档 (PDF)于2 December 2022）.
- ^ Daclatasvir (Daklinza) Use During Pregnancy. Drugs.com. [2 December 2022]. （原始内容存档于6 December 2021） （英语）.
- ^ Sofosbuvir (Sovaldi) Use During Pregnancy. Drugs.com. [2 December 2022]. （原始内容存档于5 February 2020） （英语）.
- ^ Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC). Electronic Medicines Compendium. September 2016. （原始内容存档于2016-11-09）.
- ^ Sovaldi 400 mg film coated tablets - Summary of Product Characteristics. UK Electronic Medicines Compendium. September 2016 [10 November 2016]. （原始内容存档于10 November 2016）.
- ^ Abraham, GM; Obley, AJ; Humphrey, LL; Qaseem, A; Scientific Medical Policy Committee of the American College of, Physicians; Centor, RM; Akl, E; Forceia, MA; Haeme, R; Hamilton, PG; Hood, GA. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians.. Annals of internal medicine. January 2021, 174 (1): 98-100. PMID 33017566. doi:10.7326/M19-3860.
- ^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.
